Home » Botox Lawsuit » Infection
Receive a free case review.
After receiving reports linking Botox, Botox Cosmetic and Myobloc to droopy eyelids, numbness, headaches, and swallowing and breathing problems, the U.S. Food and Drug Administration (“FDA�) mandated that manufacturers of licensed botulinum toxin products add a Black Box Warning regarding the risk of Botox infection. Botox infection occurs when the effects of the toxin spread beyond the injection site. In addition to the Black Box Warning, the FDA is requiring Botox manufacturers to develop and implement a Risk Evaluation and Mitigation Strategy (“REMS�) to provide more information on how botulinum toxin products can lead to Botox infection. Furthermore, the FDA is also requiring drug makers to distribute a Medication Guide alerting patients of the potential risk of Botox infection, and to submit safety records.
Botulinum toxin, the active ingredient in Botox, Botox Cosmetic
|
Related Topics: Dangerous Product Alerts: |
The reported signs and symptoms of a potential Botox infection include:
The Botox FDA Warning is a Black Box warning, which is the FDA’s strongest type. In January 2008, the consumer advocacy group, Public Citizen, petitioned the FDA to add a Botox FDA Warning on the products’ labels because of the serious risks associated with Botox infection, and cited 180 cases of U.S. patients suffering fluid in the lungs, difficulty swallowing or pneumonia, including 16 deaths.
If you or a loved one suffered injuries caused by a Botox injection, contact us today for a confidential and free case evaluation to see if you qualify for a Botox lawsuit.
Botox
Botox Cosmetic
Botulinum Toxin Type A
Myobloc
Botulinum Toxin Type B
1989
Black Box Warning
Wrinkles
Migraine Headaches
Hyperhidrosis
Birth defects
Pnuemonia
Respiratory Failure
Paralysis
Botulism
Death
Botax
Botux